Searched for
BAUSCH LOMB
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...- For those who still have patience for long-term investing: 5 large-caps from different sectors with upside potential of up to 30%The Indian markets are closed for trading, but the oil price is reacting to overnight noise on the US-Iran war. So, will we see more weakne...
- L'Oreal, Dyson, Bausch + Lomb become the latest to sue for Trump tariff refundsFrench beauty giant L'Oreal, UK-based Dyson and contact lens maker Bausch + Lomb have sued for refunds of tariffs imposed under US Presiden...
- Lupin launches generic ophthalmic medication in USLupin, an Indian drug firm, has introduced a generic eye medication in the US. This medication, Loteprednol Etabonate Ophthalmic Suspension...
- Canada's TSX hits record high as investors assess economic dataCanada's main stock index inched up to an all-time high on Friday, but losses in heavyweight mining shares kept gains in check, while inves...
- After share surge, contact lens maker Bausch + Lomb says it is exploring saleBausch + Lomb also said its statement was in response to a request from the Canadian Investment Regulatory Organization (CIRO) after a seri...
- TPG, Blackstone bid for Bausch + Lomb in potential $14 billion dealTPG and Blackstone are teaming up to bid for Bausch + Lomb, with an expected valuation between $13 billion and $14 billion. This sale, mana...
- Alembic Pharma gets USFDA nod for generic Bromfenac ophthalmic solutionAlembic Pharmaceuticals Ltd has obtained final approval from the US FDA for its generic Bromfenac ophthalmic solution, used to treat postop...
- Lupin gets USFDA nod for Bromfenac Ophthalmic SolutionPharma major Lupin on Wednesday said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solut...
- Dabur appoints Biplab Baksi as HR headBaksi graduated in Electronics & Communications from IET, Lucknow in 1989 and has a Masters degree in Business Administration- HR from XLRI...
- Lenskart puts aside Rs 71 crore to build its contact lens unitLenskart will spend on product innovation, backend integration and enabling trials, while positioning it as a fashion category.
- Up in the air: Bausch & Lomb MD Sanjay Bhutani likes to play Sudoku, solve crossword puzzlesThese two games help Bhutani keep his mind sharp.
- Microsoft India HR head Rohit Thakur to join AccentureHe has also worked with Eicher Goodearth (tractors division), Bausch and Lomb India, and Cadence Design Systems, among others.
- Online photography marketplace Picsdream raises angel fundingIndian Angel Network co-founder Raman Roy has led the angel round with other investors. The funding will propel marketing and boost product...
- Bausch & Lomb to market Bosch's innovative eye-care deviceGlobal vision care major Bausch & Lomb has entered into a partnership with technology firm Bosch to market the latter's digital Fundus came...
- Bausch + Lomb mulls strengthening surgical business portfolioThe recent acquisition of Synergetics USA, Inc will provide additional impetus to the firm's portfolio expansion plans in the country, it s...
- Bausch + Lomb eyeing expansion to 800 townsVision care company Bausch + Lomb, a part of the health and wellness firm, Valeant Pharmaceuticals International is looking to expand its p...
- Our research is aimed at perfecting vision: Harish Natarajan, MD Bausch & Lomb IndiaEarly this year B&L launched `i-connect’ the India youth lens. I-connect allows users to experience lenses at an entry point of Rs 500.
- Bausch & Lomb enters Pharmaceutical marketEyecare firm Bausch & Lomb has entered into a drug supply deal with Bangalore-based Micro Labs, marking its entry into the country’s pharma...
- Bausch & Lomb plans pharma forayBausch & Lomb plans to enter the ophthalmic pharmaceutical market in India. As of now, its Indian subsidiary is engaged in two product line...
Load More
